Logo

CERO

CERo Therapeutics Holdings, Inc.

CERO

CERo Therapeutics Holdings, Inc. • NASDAQ
$0.07 ▼ -8.33% (-0.01)
Market Cap $79553
52w High $412.00
52w Low $0.05
Dividend Yield 0%
P/E -0.01
Volume 15.99K
Outstanding Shares 1.21M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.363M ▼ $-11.506M ▼ 0% $-9.1 ▲ $-4.363M ▲
Q2-2025 $0 $4.724M ▼ $-5.417M ▼ 0% $-61.71 ▼ $-5.163M ▼
Q1-2025 $0 ▼ $4.951M ▲ $-5.106M ▼ 0% ▼ $-3.18 ▼ $-4.837M ▼
Q4-2024 $1.163M ▲ $2.384M ▼ $1.244M ▲ 107.008% ▲ $0.56 ▲ $1.546M ▲
Q3-2024 $0 $4.402M $-4.228M 0% $-17.02 $-4.402M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.022M ▼ $3.911M ▼ $8.455M ▲ $-4.543M ▼
Q2-2025 $3.803M ▼ $6.202M ▼ $7.836M ▼ $-1.634M ▼
Q1-2025 $5.204M ▲ $7.991M ▲ $8.321M ▲ $-329.386K ▲
Q4-2024 $3.327M ▼ $6.207M ▼ $8.101M ▼ $-1.895M ▲
Q3-2024 $3.38M $6.492M $10.194M $-3.702M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.856M ▲ $-3.205M ▲ $500K ▲ $1.425M ▼ $-1.281M ▲ $-3.205M ▲
Q2-2025 $-5.417M ▼ $-4.623M ▼ $0 $2.722M ▼ $-1.901M ▼ $-4.623M ▼
Q1-2025 $-5.106M ▼ $-4.446M ▼ $0 ▲ $6.322M ▲ $1.876M ▲ $-4.446M ▼
Q4-2024 $-1.048M ▼ $-1.54M ▲ $-4 ▼ $1.487M ▼ $-53.144K ▲ $4.146M ▲
Q3-2024 $-4.227K $-2.758M $0 $2.492M $-266.822K $-1.318M

Five-Year Company Overview

Income Statement

Income Statement CERO is a pure research-stage biotech: it has essentially no revenue yet and is funding scientific work through losses. The operating loss so far looks modest in absolute terms, but the company is clearly not close to commercialisation. The very large swings in reported loss per share mainly reflect reverse stock splits and changes in share count rather than a dramatic change in the underlying business. Overall, this is a classic early-clinical biotech profile: expenses are almost entirely research and corporate overhead, with no offsetting income from products or partnerships so far.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small pool of assets and cash, no financial debt, and a thin layer of equity. At one point equity dipped negative, which signals cumulative losses have already eaten through previously raised capital, though it has since moved back into slightly positive territory. The absence of debt reduces pressure from lenders, but the small asset base and limited cash mean the company is dependent on raising new funds over time to keep trials moving. This is a lean, high-risk balance sheet typical of a young biotech that has not yet secured major partnerships or product revenue.

Cash Flow

Cash Flow Cash flows show a straightforward pattern: money is flowing out to fund operations, with no meaningful investment in long-lived assets and no cash coming in from the business itself. Operating and free cash flow are both negative and closely matched, which means nearly every dollar spent is going into running the research operation rather than building facilities or equipment. While the absolute burn rate appears relatively small, the company still needs periodic external financing to sustain its programs, and its cash position does not offer a long runway by itself.

Competitive Edge

Competitive Edge On the scientific side, CERO is differentiated: it is pursuing a novel T‑cell approach that aims to combine direct cancer killing with an engulfment mechanism and broader immune activation. The platform targets a marker present on many tumors, which, if proven in the clinic, could support use across multiple cancers. The company has built a meaningful patent portfolio around this chimeric engulfment receptor technology, including its lead candidate and combination strategies with other cell therapies, and those patents extend well into the next decade. Against that, CERO is small, early in development, and operates in a very crowded immuno‑oncology field dominated by far larger players. Its competitive position therefore depends heavily on generating strong clinical data and securing collaborations or partnerships to scale.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of CERO’s story. The CER‑T platform is designed to be a next-generation step beyond traditional CAR‑T, with a dual mechanism that could make it more versatile and possibly more durable if the science holds up. The lead program, targeting a blood cancer, is already in an early human trial with initial safety signals that appear acceptable enough to move to higher doses. Preclinical work suggests potential use in solid tumors as well, and the company is thinking ahead to combination regimens and new pipeline candidates, supported by a relatively broad set of patents. At the same time, everything is still at an early, high‑uncertainty stage: clinical proof of concept, long‑term safety, manufacturability, and regulatory acceptance all remain to be demonstrated.

Summary

CERO is an early‑stage, high‑science biotech with a distinctive cell‑therapy platform but an extremely immature financial profile. The company currently has no product revenue, a very small asset and cash base, and ongoing cash burn typical of a research organisation. Multiple reverse stock splits and thin equity highlight financing and listing pressures, and future progress will likely depend on the company’s ability to raise additional capital or secure partners. The main source of potential value lies in its novel CER‑T technology and growing intellectual property estate, with a lead program already in a Phase 1 trial and ambitions to move into solid tumors and combination therapies. Overall, this is a classic binary biotech setup: substantial scientific upside if the platform works and is funded through later stages, but significant financial and execution risk along the way.

NEWS

November 5, 2025 · 8:00 AM UTC

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

Read more

November 4, 2025 · 9:05 AM UTC

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

Read more

October 29, 2025 · 7:22 PM UTC

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Read more

October 21, 2025 · 8:15 AM UTC

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Read more

October 15, 2025 · 8:30 AM UTC

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

Read more